pharma · Anemia · Anemia Associated With Chronic Kidney Disease · AKBA
Akebia Europe
Akebia Europe Limited
Akebia Europe is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker AKBA. Primary therapeutic focus areas include Anemia, Anemia Associated With Chronic Kidney Disease, Anemia of Chroni
Cambridge, USA HQ
2007 Founded
271 Employees
Public company Type
AKBA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2007
- Employees
- 271
- Programs
- 25
- Drugs
- 13
- Patents
- 28
Praliciguat
Phase 2 · small molecule · Focal Segmental Glomerulosclerosis
Praliciguat for Focal Segmental Glomerulosclerosis is a Phase 2 program (small_molecule) at Akebia Europe Limited with 1 ClinicalTrials.gov record(s).
Internal code AKB-1973-CI-0001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Akebia Europe Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Focal Segmental Glomerulosclerosis
- Status
- active
- Trials
- 1